Concepedia

Katja Rohwedder

KR

Statistics

Publications

24

Citations

1.9K

H-Index

16

Active since

2011

Affiliations

Bayer (Germany)(Current)

University of Michigan

AstraZeneca (Germany)

Université de Lorraine

University of Glasgow

Katja Rohwedder is an author at Bayer (Germany) specializing in pharmacology, medicine, and diabetes mellitus.

Publications per year

2011–2025

24

Publications

24

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin

Michael A. Nauck, Stefano Del Prato, Juris J. Meier et al. · Diabetes Care · 2011 · 531 citations · Full text

, , +17

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

John Wilding, Vincent Woo, Katja Rohwedder et al. · Diabetes Obesity and Metabolism · 2013 · 295 citations · Full text

, , +17

Long‐term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add‐on therapy to metformin in patients with type 2 diabetes: 4‐year data

Stefano Del Prato, Michael A. Nauck, S. Durán‐García et al. · Diabetes Obesity and Metabolism · 2015 · 229 citations

, , +17

Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial

S. Matthäei, Keith Bowering, Katja Rohwedder et al. · Diabetes Care · 2015 · 148 citations

, , +16

Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

Michael A. Nauck, Stefano Del Prato, S. Durán‐García et al. · Diabetes Obesity and Metabolism · 2014 · 114 citations

, , +17

1–5 of 24